MCC1019 is a selective PLK1 PBD inhibitor with an IC50 of 16.4 µmol/L. MCC1019 inactivates the AKT signaling pathway in cancer cells, and induces Apoptosis, Necroptosis and Autophagy. MCC1019 exhibits anticancer activity against lung cancer and prostate cancer[1][2].